Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Trial Profile

A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Epoetin alfa (Primary) ; Iron sucrose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOPE-Hb
  • Most Recent Events

    • 04 Sep 2018 Planned initiation date changed from 21 May 2018 to 1 Oct 2018.
    • 21 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top